This announcement is a separate document:
Heartseed:Heartseedは、HS-001を投与した第1/2相臨床試験の用量漸増に関する安全監視委員会からの肯定的な勧告を発表しました
Heartseed: Heartseed announced a positive recommendation from the safety monitoring committee regarding dose escalation in Phase 1/2 clinical trials administered with HS-001.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.